A patent refusal order in India that lists prior art and asserts obviousness, without mapping claims, without engaging with the applicant’s technical arguments, and without explaining why a person skilled in the art would combine the cited references, is not a reasoned order. It is a template. And on 18 February 2026, the Delhi High Court held that template unsustainable in law.
In Fertin Pharma A/S v. Assistant Controller of Patents and Designs, C.A.(COMM.IPD-PAT) 25/2023, Justice Tushar Rao Gedela set aside a refusal order that followed precisely this pattern. Prior art listed, obviousness concluded, applicant’s submissions acknowledged but not engaged. The Court held that the Section 15 mandate requires the Controller to show his work. Reciting prior art is not showing work. Asserting a conclusion is not analysis. A closing line that asserts obviousness without the reasoning that supports it is doing the analytical work the body of the order never performed.
For pharmaceutical and chemical patent prosecution in India, this decision changes the commercial calculus on every borderline refusal. The question that startups, in-house counsel, and foreign associates have consistently answered incorrectly, appeal or abandon, now has a different analytical foundation.
What Section 15 Actually Requires and What the Controller Has Been Doing Instead
Section 15 of the Patents Act, 1970 empowers the Controller to refuse an application that does not comply with the Act. That power is discretionary, and discretionary powers exercised by quasi-judicial authorities must be supported by reasons. An order without reasons is no order in law. This is settled Supreme Court jurisprudence that predates the Patents Act in its current form and applies to every quasi-judicial proceeding in India.
Fertin Pharma applies that settled standard to patent prosecution specifically. The patent refusal order India practitioners have been receiving for years, and accepting as substantive decisions, must now meet a higher threshold. The Controller must identify the closest prior art rather than merely listing every cited document. He must map each claim feature to the prior art disclosure rather than asserting that the claims are anticipated or obvious. He must address the technical effect the applicant has pleaded across the FER response and the oral hearing submissions rather than summarising those submissions in a paragraph and then disregarding them. He must explain the combinatorial logic, specifically why a person skilled in the art would combine D2 with D3 in the manner alleged, rather than assuming that because the combination seems obvious to the Controller it is obvious to the skilled person.
This is not a new standard in the abstract. The requirement of reasoned orders in quasi-judicial proceedings is foundational administrative law. What Fertin Pharma does is apply it concretely to the specific pattern that Indian patent prosecution has produced and hold, explicitly, that the pattern fails.
The Misreading That Has Cost Applicants Priority Dates
The commercial consequence of this pattern, and of the misreading that has followed it, is significant particularly in pharmaceutical and chemical prosecution where the priority date often represents the entire commercial value of a molecule.
The misreading is straightforward. When in-house counsel or a foreign associate receives a refusal order from the Indian Patent Office, the natural assumption is that the Controller has weighed the prior art and assessed the technical merit. The order looks like a decision. It reproduces the claims. It lists the prior art. It refers to the applicant’s response. It reaches a conclusion. The structure implies analysis.
That implication is frequently false. The structure of the order does not establish that the analytical work was performed. In many cases, and Fertin Pharma is one of them, the work was not performed. The claims were not mapped. The technical arguments were not engaged. The combinatorial logic was never explained. The order simply concluded, in a closing line that asserted what the body never demonstrated.
When in-house counsel or a foreign associate instructs a client to abandon on the basis of such an order, the priority date is lost. In pharmaceutical prosecution that loss may be irreversible. The molecule’s patent protection window is defined by the priority date. Refiling after abandonment means refiling without the original priority, which in a competitive generic environment frequently means filing a patent that will be challenged from the moment of grant on prior art that would not have existed at the original priority date. Fertin Pharma establishes that this calculation was based on a false premise. A cryptic refusal is not a reasoned refusal. It is an appealable one.
The Section 117A Appeal and a Recalculated Cost-Benefit
For prosecution counsel managing Indian patent portfolios, the practical implication of Fertin Pharma is a fundamental recalculation of the Section 117A appeal.
A Section 117A appeal to the Commercial Division of the Delhi High Court involves court fees, drafting costs, and a timeline of roughly eight to fourteen months from filing to hearing in a straightforward matter. These costs are real. For an early-stage innovator or a mid-sized pharmaceutical company managing a large portfolio they are not trivial. But the comparison is wrong if the alternative is refiling with a lost priority date.
Refiling costs the priority date permanently. In pharmaceutical and chemical inventions the priority date is not a procedural formality. It is the boundary condition that defines the patent’s commercial value. A molecule protected from the priority date is a different commercial asset from the same molecule protected from the refiling date, measured against the prior art that exists at the later date. The commercial difference can be the difference between a defensible patent and an indefensible one.
A successful Section 117A appeal with remand to a different officer preserves the priority date. The original application, with its original priority, goes back before a fresh decision-maker who is required by the remand order to conduct the analysis the first order omitted. If the applicant has built the prosecution record correctly, through a tight FER response, hearing submissions that articulate the technical advance claim by claim, and Form 13 amendments that narrow the claims to defensible scope, the remand is an opportunity to obtain a grant on the original priority date that the defective refusal denied.
For in-house counsel at Indian innovators managing portfolios of refused applications, Fertin Pharma is also a retrospective audit signal. Applications refused in the last twenty-four months with thin, template-style orders are not necessarily write-offs. They are potentially appealable assets where the priority date is recoverable if the refusal order does not meet the standard the Court has now confirmed. Running that audit, and running the cost-benefit on each thin refusal against the value of the priority date at stake, is a portfolio management exercise that this decision makes commercially rational.
What Fertin Pharma Does Not Mean
Clarity on the limits of the decision is as important as clarity on its implications.
Fertin Pharma does not mean every patent refusal in India is appealable on procedural grounds. Where the Controller has performed the analysis, has mapped claims to prior art, has addressed the technical arguments, has explained the combinatorial logic, the order stands. The Court will not substitute its view for the Controller’s on the merits of inventive step. The standard is procedural and not substantive. A well-reasoned refusal based on prior art that genuinely anticipates or renders obvious the claimed invention is not affected by this decision.
Nor does Fertin Pharma rescue applicants who have not built the prosecution record. The decision rewards applicants who made the case at the FER stage and at the oral hearing, applicants who gave the Controller the technical arguments that a reasoned refusal must engage with. Where the FER response is thin, where the hearing submissions do not articulate the technical advance, where the prosecution record does not give the Controller anything substantive to work with, the remand to a different officer may produce the same outcome. A different officer who performs the analysis properly may still refuse because the record does not support a grant. The principle cuts both ways. Fertin Pharma makes cryptic refusals appealable. It also makes thin prosecution records vulnerable on remand.
The Prevention Calculation
For pharmaceutical and chemical applicants in India, the most important implication of this decision is not the appeal itself. It is the prevention that makes the appeal unnecessary.
A tight FER response, drafted by counsel who understands both the Indian examination environment and the technical subject matter, costs roughly one-third of a Section 117A appeal after a defective refusal. A hearing submission that locks in every technical argument on record, articulated claim by claim against the prior art combination the examiner has proposed, costs roughly one-fifth of an appeal conducted on a thin record. A Form 13 amendment that narrows the claims to defensible scope before refusal is a fraction of the cost of remand proceedings before a different officer.
For pharmaceutical applicants managing molecules where the priority date carries the entire commercial value of the patent, this prevention calculation is unambiguous. Build the record at the FER stage. Build it again at the hearing. Make the Controller’s job of writing a reasoned refusal so difficult that the only analytically honest order is a grant.
Using Fertin Pharma as Leverage
Fertin Pharma is now the authority that changes the dynamic at the prosecution stage, before refusal and not only after it.
Cite it in the FER response. Cite it in the written submissions for the oral hearing. Put the Controller on notice, explicitly, that a refusal order which does not meet the Section 15 standard confirmed by the Delhi High Court will be appealed under Section 117A and is likely to be remanded. The Controller is a quasi-judicial authority who knows the law and Fertin Pharma gives the applicant’s counsel the authority to invoke it directly in prosecution, not as a threat but as a statement of the legal standard the order must meet.
For foreign associates advising clients on Indian prosecution strategy, Fertin Pharma is the decision to read before the next instruction to abandon. Read the refusal order against the FER, the hearing submissions, and the cited prior art. If it does not engage, does not map, does not explain, the appeal is rational, the priority date is recoverable, and the commercial calculation is different from what it was before 18 February 2026.
Comments are closed